Human melanoma cell lines deficient in G(D3) ganglioside expression exhibit altered growth and tumorigenic characteristics

Journal of Investigative Dermatology

Volumn 107, Issue 4, 1996, Pages 543-548

  Nakano, Junji ^a   Mohan Raj, Bhaskara K ^a   Asagami, Chidori ^b   Lloyd, Kenneth O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell pigmentation; Glycolipids; Glycosyltransferase

Indexed keywords

GANGLIOSIDE GD3;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029819262     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12582802     Document Type: Article

References (27)

1. Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN: Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 7:2315-2321, 1992
2. Cheresh DA, Harper JR, Schulz G, Reisfeld RA: Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81:5767-5771, 1984
3. Furukawa K, Clausen H, Hakomori S, Sakamoto J, Look K, Lundblad A, Mattes MJ, Lloyd KO: Analysis of the specificity of five murine anti-blood group A monoclonal antibodies, including one that identifies type 3 and type 4 A determinants. Biochemistry 24:7820-7826, 1985
4. Furukawa K, Lloyd KO: Gangliosides in melanoma. In: Human melanoma: immunology, diagnostics, and therapy. Ferrone S, ed. Heidelberg: Springer-Verlag, pp. 15-30, 1990
5. Hakomori S: Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions. J Biol Chem 265:18713-18716, 1990
6. Hakomori S-I: New directions in cancer therapy based on aberrant expression of glycosphingolipids: anti-adhesion and ortho-signaling therapy. Cancer Cells 3:461-470, 1991
7. Hamilton WB, Helling F, Lloyd KO, Livingston PO: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int J Cancer 53:566-573, 1996
8. D2 monoclonal antibody. Proc Natl Acad Sci USA 91:10455-10459, 1994
9. Ichikawa S, Nakajo N, Sakiyama H, Hirabayashi Y: A mouse B16 melanoma mutant deficient in glycolipids. Proc Natl Acad Sci USA 91:2703-2707, 1994
10. Kleinman HK, Martin GR, Fishman PH: Ganglioside inhibition of fibronectin-mediated cell adhesion to collagen. Proc Natl Acad Sci USA 76:3367-3371, 1979
11. Lloyd KO, Gordon CM, Thampoe IJ, DiBenedetto C: Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition. Cancer Res 52:4948-4953, 1992
12. Nakakunia H, Sanai Y, Shiroki K, Nagai Y: Gene-regulated expression of glycolipids: appearance of GD3 ganglioside in rat cells on transfection with transforming gene E1 of human adenovirus type 12 DNA and its transcriptional subunits. J Biochem 96:1471-1480, 1984
13. Nojiri H, Takaku F, Miura Y, Saito M: Changes in glycosphingolipid composition during differentiation of human leukemic granulocytes in chronic myelogenous leukemia compared with in vitro granulocytic differentiation of human promyelocytic leukemia cell line HL-60. Cancer Res 45:6100-6106, 1985
14. Nores GA, Dohi T, Taniguchi M, Hakomori S: Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J Immunol 139:3171-3176, 1987
15. Paller AS, Arnsmeier SL, Chen JD, Woodley DT: Ganglioside GT1b inhibits keratinocyte adhesion and migration on a fibronectin matrix. J Invest Dermatol 105:237-242, 1995
16. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ: GD3, a prominent ganglioside of human melanoma. Detection and characterization by a mouse monoclonal antibody. J Exp Med 155:1133-1147, 1982
17. Ravindranath MH, Tsuchida T, Morton DL, Irie RF: Ganglioside GM3: GD3 ratio as an index for the management of melanoma. Cancer 67:3029-3035, 1991
18. Ruan S, Lloyd KO: Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells: relative glycosyltransferase levels determine ganglioside patterns. Cancer Res 52:5725-5731, 1992
19. Ruan S, Mohan Raj BK, Furukawa K, Lloyd KO: Analysis of melanoma cells stably transfected with β1,4GaINAc transferase (GM2/GD2 synthase) cDNA: relative glycosyltransterase levels play a dominant role in determining ganglioside expression. Arch Biochem Biophys 323:11-18, 1995
20. Schengrund C-L: The role(s) of gangliosides in neural differentiation and repair: a perspective. Brain Res Bull 24:131-141, 1990
21. Schnaar RL: Glycosphingolipids in cell surface recognition, Glycobiology 1:477-485, 1991
22. Seyfried TN, Yu RK: Ganglioside GD3: Structure, cellular distribution, and possible function. Mol Cell Biochem 68:3-10, 1985
23. Svennerholm L: Chromatographic separation of human brain gangliosides. Neurochemistry 10:613-623, 1963
24. Tsuruoka T, Tsuji T, Nojiri H, Holmes EH, Hakomori S: Selection of a mutant cell line based on differential expression of glycosphingolipid, utilizing anti-lactosyl-ceramide antibody and complement. J Biol Chem 268:2211-2216, 1993
25. Weis FMB, Davis RJ: Regulation of epidermal growth factor receptor signal transduction: role of gangliosides. J Biol Chem 265:12059-12066, 1990
26. Welt S, Carswell EA, Vogel CW, Oettgen HF, Old LJ: Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin Immunol Immunopathol 45:214-229, 1987
27. Zebda N, Pedron S, Rebbaa A, Portoukalian J, Berthier-Vergnes O: Deficiency of ganglioside biosynthesis in metastatic human melanoma cells: relevance of CMP-NeuAc:LacCer α2-3 sialyltransferase (GM3 synthase). FEBS Lett 362:161-164, 1995